arrow
W

Wen-Kai Weng

stanford university school of medicine
H指数:26
被引数:4,391

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Brexucabtagene autoleucel 用于 BTKi 初治的复发/难治性套细胞淋巴瘤:ZUMA-2 研究队列 3 的主要分析

Blood
IF23.1
2025-10-310
PRE
ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome

ASTCT和USCLC关于在皮肤T细胞淋巴瘤(mycosis fungoides和Sézary综合征)中异基因干细胞移植的临床实践建议

2025-04-060
PRE
Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

ZUMA-2队列3初步分析:在初治布托替尼酪氨酸激酶抑制剂(BTKi)的复发/难治性套细胞淋巴瘤(R/R MCL)患者中应用Brexucabtagene autoleucel(Brexu-Cel)。

BLOOD
IF23.1
2024-11-051
PRE
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplantin Mcosis Fungoides and Sezary Syndrome
2024-11-010
PRE
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-speci fi c expansion and toxicity
2024-06-258
OAAI
Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD
2024-02-284
OAAI
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era

异基因造血细胞移植治疗成人急性淋巴细胞白血病

2022-08-014
OAAI
Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report
2022-04-0114
OAAI
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia
2021-08-2027
OA
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

CD19和CD22双重靶向CAR T细胞治疗复发性或难治性b细胞恶性肿瘤的1期临床试验

2021-07-26360
OAAI
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide plus /- Plerixafor versus Granulocyte Colony-Stimulating Factor plus /- Plerixafor in the Lenalidomide Era
2021-07-0116
OAAI